DYAI Dyadic: Earnings per share for the trailing year

Public company logo of Dyadic International (DYAI)

The current YoY EPS shift over the last 12 months for Dyadic International (DYAI) demonstrates volatility, with the value stabilizing at -14.30. This trend is supported by the authority of biochemists developing the C1 system. Business efficiency is based on outsourcing clinical tests to third-party CROs, which reduces costs. The foundation for growth is an innovative fungal platform for the rapid production of vaccines and antibodies on an industrial scale.

DYAI Dyadic International Inc Earnings per share for the last twelve months (02/11/2024 - 11/13/2026)

Financial and market metric breakdowns for Dyadic (DYAI)

- market price and analyst price targets:
Market Chart Dyadic International|DYAI - Price Target Chart
- company stock capitalization data:
Market Value Dyadic International Inc|DYAI - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Dyadic International|DYAI - Company Book Value|Market Capitalization to Book Value dyadic.com|DYAI - Company Total Assets
- debt burden and liquidity indicators:
Debt to Equity Ratio Dyadic International|DYAI - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Dyadic International|DYAI - Company Aggregate Debts|Debts to Book Capitalization Dyadic International Inc|DYAI - Company Long-Term Debts|Company Short-Term Indebtedness Dyadic International|Interim Coverage Ratio dyadic.com
- earnings and multiples data:
DYAI - Net Profit|Future Profit Dyadic International|DYAI - Price to Earnings Ratio|Future Price to Earnings Multiple Dyadic International|DYAI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dyadic International Inc|DYAI - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Dyadic International|DYAI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months dyadic.com|DYAI - Earnings growth in current year|Expected net earnings per share growth next year Dyadic International
Fundamental company valuation:DYAI - Dyadic International, Inc.
Finished products of Dyadic International Inc

Dyadic International (DYAI) leverages a unique biotechnological foundation with patented fungal strains to create formidable barriers to entry for competitors, directly impacting profit scalability. By analyzing the relative YoY EPS growth over the last 12 months, investors can assess net income per share dynamics, enabling them to identify cost management efficiency and determine the company's investment cycle stage relative to its market peers.

Competitor analysis for Dyadic International

Net earnings per share for the last four quarters gilead.com GILD|Cidara Therapeutics Corp (CDTX) - Earnings per share for the last twelve months|Novavax Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months CVAC|Net earnings per share (EPS TTM) Valneva Vaccines|Earnings per share for the last twelve months Vir Biotechnology, Inc. (VIR)|Net earnings per share for the last four quarters siga.com|Net earnings per share (EPS TTM) EBS (Emergent BioSolutions Inc.)|AVIR: Earnings per share for the last 12 months|IVVD: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Enanta Pharmaceuticals, Inc|INO: Net earnings per share (EPS TTM)|hillevax.com (HLVX) - Net earnings per share (EPS TTM)|KLRS (Kalaris Therapeutics) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NNVC (NanoViricides Corp)|Net earnings per share (EPS TTM) TLPH|Net earnings per share for the last four quarters Cocrystal Pharma Corp|Net earnings per share (EPS TTM) TRAW (Traws Pharma)|DWTX - Net earnings per share for the last 12 months|QLGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year ALVR (AlloVir, Inc.)|VBIV: Net earnings per share (EPS TTM)|VIRI - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Vaxart Inc.